# Evaluation Study of New Compounds With Potential Use in Schizophrenia

> **NCT00916201** · PHASE1 · WITHDRAWN · sponsor: **Central Institute of Mental Health, Mannheim**

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** URB597
- **DRUG:** intranasal Insulin
- **DRUG:** Cannabidiol CR

## Key facts

- **NCT ID:** NCT00916201
- **Lead sponsor:** Central Institute of Mental Health, Mannheim
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-31
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2025-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916201, "Evaluation Study of New Compounds With Potential Use in Schizophrenia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00916201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*